VersaCoat Nerve Protector (VTP-44G2); VersaCoat Nerve Protector (VTP-12G1)

VersaCoat Nerve Protector is an absorbable implant consisting of a hollow cylindrical hydrogel pellet (alginate and hyaluronic acid) and a wetting solution (aqueous citrate) that together form a viscous, tissue-adherent gel. It is indicated for management of peripheral nerve injuries where there has been no substantial loss of nerve tissue, functioning as a protective, non-constricting interface between injured nerves and surrounding tissues to facilitate healing.

The subject device differs from the predicate (VersaWrap Nerve Protector) only in the physical form of the hydrogel: changed from a flat sheet to a hollow cylindrical pellet to improve ease of application as a gel. When implanted, the subject and predicate devices are chemically and functionally identical, composed of the same materials (alginate, hyaluronic acid, citrate).

ISO 10993-3 (genotoxicity), ISO 10993-5 (cytotoxicity), ISO 10993-6 (subchronic toxicity and muscle implantation), ISO 10993-10 (sensitization and irritation), ISO 10993-11 (acute systemic toxicity and pyrogenicity). Sterilization validation to achieve SAL 10-6 and bacterial endotoxin testing (<20 EU/device).

The device is substantially equivalent because the change in geometry from flat sheet to cylindrical pellet is non-critical to therapeutic function and does not affect safety or effectiveness when used as labeled. Animal studies demonstrated the subject device performs similarly to the predicate in nerve injury models with no new adverse events, and comprehensive biocompatibility testing showed no new safety concerns. The identical implanted composition, shared mechanism of action (providing a gliding surface and tissue separation), and identical indications for use support substantial equivalence despite the minor formulation change.